fbpx
SKIP TO MAIN CONTENT

News

FDA approves first topical treatment for angiofibromas

April 4, 2022: The TSC Alliance® applauds the U.S. Food and Drug Administration’s (FDA’s) approval of HYFTOR™, which is the first FDA-approved topical treatment for facial angiofibromas in adults and children six years of age or older who have tuberous sclerosis complex (TSC). HYFTOR™, manufactured by Nobelpharma America, LLC, has Orphan Drug Status for this particular indication.

READ MORE